Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03044314 · ClinicalTrials.gov registry record · Phase 4

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

A Phase 4 study, sponsored by Duke University.

Terminated
Registry status
Phase 4
Development phase
27
Enrollment target

NCT03044314 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03044314, a Phase 4 study, was terminated before completion, sponsored by Duke University.

TERMINATED
Registry status
Phase 4
Development phase
27 participants
Enrollment target

Study Summary

This study will compare the clinical efficacy of inhaled iloprost as an invasive, selective vasodilator in the cardiac catheterization laboratory in patients with pulmonary hypertension to the gold standard of inhaled nitric oxide. It will also examine whether echocardiographic estimates of response to inhaled iloprost can predict responsiveness to invasive vasodilator testing in patients with pulmonary hypertension.

Interventions

  • DRUG Iloprost and nitric oxide administration

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-07-21
Est. Completion 2020-05-19
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03044314

The ClinicalTrials.gov registry entry for NCT03044314 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Iloprost and nitric oxide administration is the first listed.

NCT03044314 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03044314 about?

NCT03044314 is a clinical study titled "Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension". This study will compare the clinical efficacy of inhaled iloprost as an invasive, selective vasodilator in the cardiac catheterization laboratory in patients with pulmonary hypertension to the gold standard of inhaled nitric oxide. It will also examine whether echocardiographic estimates of response...

What is the current status of trial NCT03044314?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2017-07-21. Estimated completion is 2020-05-19.

What interventions are being tested in trial NCT03044314?

The interventions under investigation include: Iloprost and nitric oxide administration (DRUG).

Who is sponsoring clinical trial NCT03044314?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.